JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3969 Vatalanib
1 Citation

Target: VEGFR

Summary: VEGFR-1/-2 inhibitor,cell-permeable

≥16.85 mg/mL
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8245 Sorafenib Tosylate
1 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥31.85 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A8253 PD 173074

Target: VEGFR|FGFR

Summary: FGFR inhibitor

≥26.18 mg/mL
A8255 Sunitinib malate
2 Citation

Target: VEGFR

Summary: VEGFR/PDGFRβ/ KIT/ FLT3/RET/CSF-1R inhibitor

≥26.65 mg/mL
A1821 Ki8751

Target: VEGFR

Summary: VEGFR-2 inhibitor,potent and selective

≥23.45 mg/mL
A2949 Linifanib (ABT-869)

Target: VEGFR|PDGFR

Summary: VEGFR/PDGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.75 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A1882 Cediranib (AZD217)

Target: VEGFR

Summary: VEGFR inhibitor receptor,highly potent

≥22.52 mg/mL